KMDA

+ Watchlist + Portfolio

Kamada Ltd.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.20
52-Week Range: $6.50 – $9.35
Market Cap: $479.57M
P/E (TTM): 21.87
EPS (TTM): 0.38
Dividend Yield: 2.05%

Advanced Metrics

Price/Book: 1.78
PEG Ratio: 0.62
Return on Equity: 8.40%
Return on Assets: 4.63%
Gross Margin: 40.82%
Operating Margin: 17.32%
Profit Margin: 11.60%
Current Ratio: 4.06
Debt/Equity: 0.04
Total Debt: $11.80M
Free Cash Flow: $15.51M
Revenue Growth: 22.70%
Earnings Growth: 23.10%
Enterprise Value: $422.71M

KMDA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$129.34M	$142.52M	$160.95M	$180.46M
Cost of Revenue	$82.64M	$87.03M	$90.99M	$104.05M
Gross Profit	$46.70M	$55.49M	$69.97M	$76.41M
Research & Development	$13.17M	$13.93M	$15.19M	$12.99M
Selling, General & Admin	$25.06M	$27.45M	$30.83M	$33.84M
Operating Expenses	$42.17M	$45.43M	$49.92M	$50.17M
Operating Income	$4.53M	$10.06M	$20.05M	$26.23M
EBITDA	$10.81M	$22.44M	$27.80M	$39.25M
Pretax Income	-$2.26M	$8.43M	$13.33M	$23.47M
Income Tax	$62.00K	$145.00K	-$1.13M	$3.27M
Net Income	-$2.32M	$8.28M	$14.46M	$20.20M
Diluted EPS	-0.05	0.15	0.25	0.35
Diluted Shares	46.42M	53.68M	57.85M	57.71M

KMDA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.26M	$55.64M	$78.44M	$75.47M
Receivables	$28.36M	$21.29M	$23.20M	$28.84M
Inventory	$72.52M	$88.48M	$78.82M	$84.94M
Current Assets	$139.00M	$169.96M	$184.35M	$193.07M
Total Assets	$322.38M	$354.91M	$372.25M	$378.71M
Current Liabilities	$75.70M	$49.59M	$49.39M	$47.39M
Long-Term Debt	$12.96M	—	—	—
Total Debt	$20.60M	$8.82M	$11.06M	$11.56M
Total Liabilities	$146.36M	$110.89M	$112.79M	$109.64M
Retained Earnings	-$48.48M	-$40.20M	-$25.74M	-$17.07M
Shareholders' Equity	$176.02M	$244.02M	$259.46M	$269.07M
Working Capital	$63.30M	$120.37M	$134.96M	$145.68M

KMDA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$28.59M	$4.32M	$47.59M	$25.49M
Capital Expenditure	-$3.78M	-$5.85M	-$10.74M	-$9.85M
Free Cash Flow	$24.80M	-$1.53M	$36.85M	$15.64M
Depreciation & Amortisation	$12.15M	$12.71M	$13.81M	$14.92M
Stock-Based Compensation	$1.15M	$1.31M	$874.00K	$845.00K
Investing Cash Flow	-$3.78M	-$5.84M	-$10.74M	-$9.84M
Financing Cash Flow	-$9.34M	$22.68M	-$13.91M	-$18.34M
Dividends Paid	—	$0.00	$0.00	-$11.53M
Net Change in Cash	$15.46M	$21.15M	$22.94M	-$2.69M

KMDA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$44.02M	$44.75M	$47.01M	$44.68M	$45.24M	$54.92M
Cost of Revenue	$23.27M	$25.82M	$27.25M	$27.71M	$26.12M	$32.45M
Gross Profit	$20.75M	$18.93M	$19.76M	$16.97M	$19.12M	$22.47M
Research & Development	$4.25M	$3.22M	$2.64M	$2.89M	$2.18M	$2.20M
Selling, General & Admin	$8.71M	$8.63M	$9.32M	$7.18M	$9.98M	$10.76M
Operating Expenses	$12.95M	$11.86M	$11.95M	$13.42M	$12.16M	$12.96M
Operating Income	$7.79M	$7.07M	$7.82M	$3.55M	$6.95M	$9.51M
EBITDA	$10.42M	$9.69M	$10.35M	$8.79M	$9.43M	$14.45M
Pretax Income	$6.61M	$5.75M	$6.37M	$4.73M	$5.39M	$10.19M
Income Tax	$2.65M	-$1.62M	$1.07M	$1.17M	$1.26M	$927.00K
Net Income	$3.96M	$7.38M	$5.30M	$3.56M	$4.13M	$9.26M
Diluted EPS	0.07	0.13	0.09	0.06	0.07	0.16
Diluted Shares	56.63M	56.74M	58.84M	59.37M	59.03M	57.89M

KMDA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$76.25M	$65.98M	$72.00M	$75.47M	$32.92M	$29.47M
Receivables	$33.89M	$35.20M	$35.32M	$28.84M	$40.65M	$42.57M
Inventory	$78.36M	$82.08M	$85.41M	$84.94M	$85.44M	$86.88M
Current Assets	$188.50M	$183.27M	$192.73M	$193.07M	$199.24M	$199.57M
Total Assets	$375.11M	$368.17M	$377.21M	$378.71M	$383.02M	$383.16M
Current Liabilities	$57.05M	$45.77M	$47.84M	$47.39M	$59.78M	$49.16M
Total Debt	$11.10M	$11.41M	$11.47M	$11.56M	$11.64M	$11.80M
Total Liabilities	$123.15M	$108.22M	$111.98M	$109.64M	$123.63M	$113.60M
Retained Earnings	-$33.31M	-$25.93M	-$20.64M	-$17.07M	-$27.36M	-$18.10M
Shareholders' Equity	$251.96M	$259.95M	$265.23M	$269.07M	$259.39M	$269.56M
Working Capital	$131.45M	$137.50M	$144.90M	$145.68M	$139.46M	$150.41M

KMDA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$513.00K	$8.02M	$10.42M	$7.57M	-$291.00K	$18.07M
Capital Expenditure	-$1.47M	-$2.01M	-$3.59M	-$2.77M	-$973.00K	-$2.11M
Free Cash Flow	-$1.98M	$6.01M	$6.83M	$4.79M	-$1.26M	$15.96M
Depreciation & Amortisation	$3.61M	$3.75M	$3.76M	$3.80M	$3.85M	$3.89M
Stock-Based Compensation	$175.00K	$95.00K	$117.00K	$458.00K	$800.00K	$720.00K
Investing Cash Flow	-$1.46M	-$2.01M	-$3.59M	-$2.77M	-$41.20M	-$2.54M
Financing Cash Flow	-$293.00K	-$16.12M	-$754.00K	-$1.18M	-$856.00K	-$19.00M
Dividends Paid	$0.00	-$11.53M	$0.00	$0.00	$0.00	-$14.42M
Net Change in Cash	-$2.27M	-$10.11M	$6.07M	$3.61M	-$42.34M	-$3.47M

Market Snapshot

About

Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma-derived protein therapeutics and biopharmaceutical products. The company develops, manufactures, and markets specialty pharmaceutical products with a focus on orphan indications and niche markets. Kamada's portfolio includes treatments for rare diseases such as hereditary angioedema, alpha-1 antitrypsin deficiency, and immunodeficiency disorders. The company operates its own plasma fractionation facility and partners with healthcare organizations globally to distribute its products.